Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting

NCT05633771 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 562

Last updated 2026-01-12

No results posted yet for this study

Summary

An international, multicenter, non-interventional, prospective, post-authorization, descriptive, non-PASS, study.

Conditions

Interventions

OTHER

Hyrimoz

There is no treatment allocation. Patients administered Hyrimoz by prescription that have started as routine medical treatment will be enrolled.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-16
Primary Completion
2025-12-15
Completion
2026-12-31

Countries

  • Belgium
  • France

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05633771 on ClinicalTrials.gov